Skip to Content

Caribou Biosciences, Inc.

Corporate Governance / Derivative

  • Date:
  • 4/27/2024
  • Company Name:
  • Caribou Biosciences, Inc.
  • Stock Symbol:
  • CRBU
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASDAQ: CRBU) on behalf of long-term stockholders following a class action complaint that was filed against Caribou on April 11, 2023 with a Class Period from July 23, 2021 to December 9, 2022, or pursuant to the Company’s July 2021 IPO. Our investigation concerns whether the board of directors of Caribou have breached their fiduciary duties to the company.

According to the complaint, the Company’s Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) CB-010’s treatment effect was not as durable as Defendants had led investors to believe; (ii) accordingly, CB-010’s clinical and commercial prospects were overstated; and (iii) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

If you are a long-term stockholder of Caribou, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Caribou Biosciences. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: